Generics Bulletin Editor’s Picks For Q1 2023
Highlights Across The Off-Patent Sector From January To March 2023
Executive Summary
Looking back over the first quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from January to March that include the launch of the first US Humira biosimilar, new leadership at the top of some of the industry’s biggest players, annual results and strategy updates, and multiple major industry conferences – as well as the launch of our annual awards.